BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

# ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology
**ESPS manuscript NO:** 29772
**Title:** Nanoparticle-linked antagonist for leptin signaling inhibition in breast cancer
**Reviewer's code:** 00742249
**Reviewer's country:** Japan
**Science editor:** Xue-Mei Gong
**Date sent for review:** 2016-08-29 19:52
**Date reviewed:** 2016-10-06 16:23

| CLASSIFICATION | LANGUAGE EVALUATION | SCIENTIFIC MISCONDUCT | CONCLUSION |
|---|---|---|---|
| [ ] Grade A: Excellent | [ Y] Grade A: Priority publishing | Google Search: | [ Y] Accept |
| [ Y] Grade B: Very good | [ ] Grade B: Minor language polishing | [ ] The same title | [ ] High priority for publication |
| [ ] Grade C: Good | [ ] Grade C: A great deal of language polishing | [ ] Duplicate publication | [ ] Rejection |
| [ ] Grade D: Fair | [ ] Grade D: Rejected | [ ] Plagiarism | [ ] Minor revision |
| [ ] Grade E: Poor | | [Y ] No | [ ] Major revision |
| | | BPG Search: | |
| | | [ ] The same title | |
| | | [ ] Duplicate publication | |
| | | [ ] Plagiarism | |
| | | [Y ] No | |

## COMMENTS TO AUTHORS

Comments: The authors developed a leptin antagonist linked to Iron Oxide Nanoparticles (IONP-LPrA2). IONP-LPrA2 inhibits cell proliferation especially combined with chemotherapeutics agents. This manuscript provides useful information to the medical students, clinicians, and researchers in this field, therefore, is acceptable for publication in World Journal of Clinical Oncology. That is all.

BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

# ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology
**ESPS manuscript NO:** 29772
**Title:** Nanoparticle-linked antagonist for leptin signaling inhibition in breast cancer
**Reviewer's code:** 00742373
**Reviewer's country:** United States
**Science editor:** Xue-Mei Gong
**Date sent for review:** 2016-08-29 19:52
**Date reviewed:** 2016-10-17 03:35

| CLASSIFICATION | LANGUAGE EVALUATION | SCIENTIFIC MISCONDUCT | CONCLUSION |
|---|---|---|---|
| [ ] Grade A: Excellent | [ Y] Grade A: Priority publishing | Google Search: | [ ] Accept |
| [ Y] Grade B: Very good | [ ] Grade B: Minor language polishing | [ ] The same title | [ ] High priority for publication |
| [ ] Grade C: Good | [ ] Grade C: A great deal of language polishing | [ ] Duplicate publication | [ ] Rejection |
| [ ] Grade D: Fair | [ ] Grade D: Rejected | [ ] Plagiarism | [ Y] Minor revision |
| [ ] Grade E: Poor | | [Y ] No | [ ] Major revision |
| | | BPG Search: | |
| | | [ ] The same title | |
| | | [ ] Duplicate publication | |
| | | [ ] Plagiarism | |
| | | [Y ] No | |

## COMMENTS TO AUTHORS

The manuscript titled "Nanoparticle-linked antagonist for leptin signaling inhibition in breast cancer" discussed the risk factors of TNBC, the leptin signaling activity pathway, and the effect of leptin signaling inhibition in the treatment of breast cancer cells. The authors described a coupling system of anti-TNBC chemical LprA2 to a nanoparticle delivery system which use iron oxide nanoparticles to capture multiple LprA2 peptides. They assessed the conjugation of the system to determine the inhibitory on breast cancer cell growth and survival. They found that IONP-LPrA2 abrogates the effect of leptin on leptin-induced signaling pathways, IONP-LPrA2 inhibits leptin-induced cell cycle progression of human breast cancer cell lines, IONP-LPrA2 inhibits leptin-induced cell proliferation in human breast cancer cells. The manuscript concluded that that IONP-LPrA2 may be useful in the prevention of tumor cell growth and proliferation in breast cancer. Further, treatment with IONP-LPrA2 may allow for lower chemotherapeutic dosage. Breast cancer is the second leading cause of cancer deaths in women in the US. TNBC is a subtype of breast cancer characterized by the lack of hormone receptor expression. It is more aggressive form of breast cancer even more difficult to treat. The authors of this manuscript developed a leptin antagonist linked to iron oxided

nanoparticles which inhibits celll proliferation and increase chemotherapeutics efficacy to triple negative breast cancer cell lines. It is a new point in basic research to use nanoparticles conjugated with antagonist in the treatment of TNBC cell line. Suggestions: * In Material and Methods: Reagents and Antibodies: I will suggest to put the description of the reagents and antibodies into the description of experiments by using parentheses for their source, or by using a list. * Is there any previous report for the cell cycle analysis as a reference?